German Pharma Stock News

XTRA:PUM
XTRA:PUMLuxury

PUMA (XTRA:PUM) Valuation Check After New Dedicated Training Business Unit Announcement

Why PUMA (XTRA:PUM) Is Back in Focus After Its New Training Unit PUMA (XTRA:PUM) is creating a dedicated Business Unit for Training at its Herzogenaurach headquarters, separating it from Running to sharpen category focus and simplify decisions across its wider apparel portfolio. See our latest analysis for PUMA. The Training unit announcement comes as PUMA’s share price sits at €23.15, with a strong 90 day share price return of 37.63% contrasting with a weaker 1 year total shareholder return...
XTRA:MBG
XTRA:MBGAuto

Assessing Mercedes-Benz Group (XTRA:MBG) Valuation After Recent Share Price Softness

Why Mercedes-Benz Group (XTRA:MBG) is on investors’ radar today Mercedes-Benz Group (XTRA:MBG) has drawn attention after recent share price softness, with the stock down about 3% over the past month and 6% year to date based on the latest close. See our latest analysis for Mercedes-Benz Group. At the latest share price of €58.31, Mercedes-Benz Group’s short term share price return has been slightly negative in recent weeks, while its 1 year total shareholder return of 10.1% and 5 year total...
XTRA:BAS
XTRA:BASChemicals

Is BASF (XTRA:BAS) Pricing Look Attractive After Recent Share Price Gains?

If you are wondering whether BASF at around €48.77 is offering good value today, you are not alone. This article will help you frame that question clearly. The share price has recently moved, with returns of 4.6% over 7 days, 8.5% over 30 days, 8.9% year to date, 8.6% over 1 year and 14.7% over 3 years, while the 5 year return sits at a 1.1% decline. Recent attention around BASF has focused on its position as a major European chemicals group and how it fits into broader discussions about...
XTRA:DHER
XTRA:DHERHospitality

Assessing Delivery Hero (XTRA:DHER) Valuation After Cost Cuts And Exit From Underperforming Regions

Delivery Hero (XTRA:DHER) is back in focus after management launched a broad strategy review, streamlined costs, and exited underperforming regions. These moves are reshaping how investors look at the food delivery group. See our latest analysis for Delivery Hero. The recent strategy review and cost focus comes after a sharp 7 day share price return of negative 13.89% and a 1 year total shareholder return of negative 16.96%, despite a 90 day share price return of 26.67%. This suggests that...
XTRA:TMV
XTRA:TMVSoftware

TeamViewer (XTRA:TMV) Valuation Check After New Thrive Collaboration On Proactive IT Services

TeamViewer (XTRA:TMV) has entered a new partnership with Thrive, integrating its Digital Employee Experience capabilities into Thrive's ServiceNow based NextGen managed services platform to support more proactive IT operations and automation. See our latest analysis for TeamViewer. At a share price of €5.705, TeamViewer has seen pressure build over time, with a 30 day share price return of 4.76% and a 1 year total shareholder return decline of 50.54%. Recent partnership news may be watched...
XTRA:EVK
XTRA:EVKChemicals

Evaluating Evonik Industries (XTRA:EVK) Valuation After Annual Results And Dividend Confirmation

What the latest earnings and dividend mean for Evonik Industries (XTRA:EVK) Evonik Industries (XTRA:EVK) reported full year 2025 results with sales of €14,069 million and net income of €634 million, alongside confirming an annual dividend of €1.00 per share payable in June 2026. See our latest analysis for Evonik Industries. The release of full year 2025 results, which showed sales of €14.1b and net income of €634 million, appears to be in focus for investors. The 7 day share price return of...
XTRA:SRT3
XTRA:SRT3Life Sciences

Sartorius Q4 Margin Miss Shifts Focus To Earnings Quality And Mix

Sartorius (XTRA:SRT3) reported Q4 results that missed expectations, with pressure on margins. Management issued cautious guidance, highlighting a focus on margin recovery. The company plans to prioritize higher value product rollouts as part of its response. These updates signal a potential inflection point in how Sartorius balances growth, profitability, and product mix. Sartorius, a supplier of equipment and solutions for the biopharma and life sciences industry, operates within long term...